ClinicalTrials.gg
CompletedNCT06284902Updated Sep 12, 2025

Bioavailability Study of Fexofenadine HCl New Formulation Tablet

A Phase 1 interventional study of Fexofenadine HCl Coated tablet and Fexofenadine HCl New Formulation Tablet in Healthy Volunteers, sponsored by Opella Healthcare Group SAS, a Sanofi Company. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Opella Healthcare Group SAS, a Sanofi Company (formerly part of Sanofi) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the study is to assess the relative bioavailability of a new galenic form of fexofenadine HCl new formulation tablet (test drug) taken with or without water compared to fexofenadine HCl film-coated tablets (reference form) taken with water under fasting conditions.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Opella Healthcare Group SAS, a Sanofi Company is the lead sponsor of 3 studies on the registry; none are open to participants now.

First submitted before Opella Healthcare Group SAS left Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female non-smokers (no use of tobacco or nicotine products within 3 months prior to screening), ≥18 and ≤55 years of age, with body-mass-index () >18 and \<29.9 kilogram per meter square (kg/m\^2) and body weight ≥50.0 kg to ≤100.0 kg for males and ≥40.0 kg to ≤90.0 kg for females.
  2. Healthy as defined by:

    1. the absence of illness and surgery within 4 weeks prior to inclusion on Day 1.
    2. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
  3. Standard 12-lead (ECG) parameters after 5 minutes resting in supine position in the following ranges:120 milliseconds (ms)\<PR\<220 ms, QRS\<120 ms, ≤450 ms if male, ≤470 ms if female and normal ECG tracing unless the Investigator considers an ECG tracing abnormality to be not clinically relevant.
  4. Female participants of non- must be:

    1. (spontaneous amenorrhea for at least 12 months prior to inclusion on Day 1) with confirmation by documented follicle-stimulating hormone (FSH) levels 30 milli-international units per milliliter (mIU/mL); or
    2. surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy or tubal ligation) at least 3 months prior to inclusion on Day 1.
  5. Female participants of childbearing potential who are sexually active with a non-sterile male partner (sterile male partners are defined as men vasectomized for at least 3 months prior to inclusion on Day 1) must be willing to use one of the following acceptable methods throughout the study and for 30 days after the last dose:

    1. simultaneous use of hormonal contraceptive (e.g., oral, patch, depot injection, implant, vaginal ring, intrauterine device) or non-hormonal intrauterine device used for at least 4 weeks prior to inclusion on Day 1 (must agree to use the same contraceptive throughout the study) and condom for the male partner;
    2. simultaneous use of non-hormonal intrauterine device placed at least 4 weeks prior to inclusion on Day 1 and condom for the male partner;
    3. simultaneous use of diaphragm or cervical cap with spermicide and condom for the male partner, started at least 21 days prior to inclusion on Day 1.
  6. Male participants who are not vasectomized for at least 3 months prior to inclusion on Day 1 and who are sexually active with a female partner of childbearing potential must be willing to use one of the following acceptable contraceptive methods from the first dose and for 90 days after the last dose:

    1. simultaneous use of condom and hormonal contraceptive (e.g., oral, patch, depot injection, implant, vaginal ring, intrauterine device) or non-hormonal intrauterine device used for at least 4 weeks prior to sexual intercourse for the female partner;
    2. simultaneous use of condom and a diaphragm or cervical cap with spermicide for the female partner.
  7. Male participants (including men who have had a vasectomy) with a pregnant partner must agree to use a condom from the first dose and for 90 days after the last dose.
  8. Male participants must be willing not to donate sperm for 90 days after the last dose.
  9. Willing to take off dentures or mouth piercing at the time of dosing.
  10. Able to understand the study procedures and provide signed to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Any abnormal finding at physical examination at screening.
  2. Clinically significant abnormal laboratory test results or positive serology test results for surface antigen (HBsAg), virus (HCV) antibody, or (HIV) antigen and antibody at screening.
  3. Frequent history of headaches and/or migraine more than twice a month, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
  4. Positive pregnancy test or lactating female participant.
  5. Positive urine drug screen, urine cotinine test, or alcohol breath test.
  6. Known allergic reactions to fexofenadine HCl or other related drugs, or to any in the formulation.
  7. Presence or history of drug , or allergic disease diagnosed and treated by a physician.
  8. Clinically significant abnormalities or vital signs abnormalities (systolic blood pressure lower than 95 or over 140 mmHg, diastolic blood pressure lower than 45 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
  9. Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease of ≥20 mmHg in systolic blood pressure, decrease of ≥10 mmHg in diastolic blood pressure, and increase of ≥30 bpm in heart rate within 3 minutes when changing from supine to standing position.
  10. History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening.
  11. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
  12. Use of medications for the timeframes specified below, with the exception of hormonal and medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the pharmacokinetic (PK) profile of the study drug or participant safety (e.g., topical drug products without significant systemic absorption):

    1. any biologics (antibody or its derivatives) given within 4 months prior to inclusion on Day 1;
    2. depot injection or implant within 3 months prior to inclusion on Day 1;
    3. any drug known to induce or inhibit cytochrome P450 (CYP)3A4 metabolism, including St. John's wort, within 30 days prior to inclusion on Day 1;
    4. prescription medications within 14 days prior to inclusion on Day 1;
    5. any vaccine, including COVID-19 vaccine, within 28 days prior to inclusion on Day 1;
    6. over-the-counter (OTC) medications and natural health products (including herbal remedies such as homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 7 days prior to inclusion on Day 1, with the exception of the occasional use of acetaminophen (up to 2 g daily);
    7. any drug known to be P-glycoproteins (Pg-p) inhibitors or inducers, Organic anion transporting polypeptides (OATP) inhibitors or inducers or any medication containing ketoconazole (e.g., Nizoral), itraconazole, verapamil, erythromycin, rifampin, and carbamazepine within 14 days prior to inclusion on Day 1 and during the study period.
    8. any antacids containing aluminum and magnesium within 14 days prior to inclusion on Day 1 and during the study period.
    9. any antihistaminic drug within 14 days prior to inclusion on Day 1.
    10. any tricyclic antidepressants within 14 days prior to inclusion on Day 1.
  13. Participation in a clinical research study involving the administration of an or marketed drug or device within 30 days prior to inclusion on Day 1, administration of a biological product in the context of a clinical research study within 90 days prior to inclusion on Day 1, or concomitant participation in an investigational study involving no drug or device administration.
  14. Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day).
  15. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first inclusion on Day 1.
  16. Presence of orthodontic braces or orthodontic retention wires or dentures, or any physical findings in the mouth or tongue that would be likely to interfere with successful completion of the dosing procedure.
  17. Presents difficulty with venipuncture and/or poor venous access.
  18. Any reason which, in the opinion of the Investigator, would prevent the participant from participating in the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Treatment Sequence Group 1

    Drug: Fexofenadine HCl Coated tablet · Drug: Fexofenadine HCl New Formulation Tablet

  • Experimental
    Treatment Sequence Group 2

    Drug: Fexofenadine HCl Coated tablet · Drug: Fexofenadine HCl New Formulation Tablet

  • Experimental
    Treatment Sequence Group 3

    Drug: Fexofenadine HCl Coated tablet · Drug: Fexofenadine HCl New Formulation Tablet

  • Experimental
    Treatment Sequence Group 4

    Drug: Fexofenadine HCl Coated tablet · Drug: Fexofenadine HCl New Formulation Tablet

  • Experimental
    Treatment Sequence Group 5

    Drug: Fexofenadine HCl Coated tablet · Drug: Fexofenadine HCl New Formulation Tablet

  • Experimental
    Treatment Sequence Group 6

    Drug: Fexofenadine HCl Coated tablet · Drug: Fexofenadine HCl New Formulation Tablet

Interventions

  • DrugFexofenadine HCl Coated tablet

    Film-coated tablet.

  • DrugFexofenadine HCl New Formulation Tablet

    New formulation tablet.

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC0-t) of Fexofenadine

    Time frame: Pre-dose and 0.17, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0, and 48.0 hours (hrs) post-dose

  2. Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) (AUC0-inf) of Fexofenadine

    Time frame: Pre-dose and 0.17, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0, and 48.0 hrs post-dose

  3. Maximal Observed Concentration (Cmax) of Fexofenadine

    Time frame: Pre-dose and 0.17, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0, and 48.0 hrs post-dose

Secondary outcomes

  1. Time When the Maximal Concentration is Observed (Tmax) of Fexofenadine

    Time frame: Pre-dose and 0.17, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0, and 48.0 hrs post-dose

  2. Time of Observation Prior to the First Observation with a Measurable (non-zero) Concentration (Tlag) of Fexofenadine

    Time frame: Pre-dose and 0.17, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0, and 48.0 hrs post-dose

  3. Terminal Half-life Associated with the Terminal Slope (T1/2z) of Fexofenadine

    Time frame: Pre-dose and 0.17, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0, and 48.0 hrs post-dose

  4. Terminal Elimination Rate Constant (Kel) of Fexofenadine

    Time frame: Pre-dose and 0.17, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0, and 48.0 hrs post-dose

  5. Percentage of Participants with Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical trial participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. A TEAE is defined as AEs that occurred or worsened at any time during the on-treatment period are defined as treatment-emergent adverse events.

    Time frame: From screening up to 7-10 days post last dose (approximately 13 weeks)

07

Study locations

1 site
  • Syneos Health Clinic inc.
    Québec, Quebec G1P 0A2, Canada
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in May 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Feb 29, 2024
StartActual
Feb 23, 2024
Primary completionActual
May 8, 2024
CompletionActual
May 23, 2024
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06284902
Responsible party
Sponsor
First posted
Feb 29, 2024
Start date
Feb 23, 2024
Primary completion
May 8, 2024
Completion
May 23, 2024
Last update
Sep 12, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion